Truist analyst Gregory Renza raised the firm’s price target on BeOne Medicines (ONC) to $412 from $400 and keeps a Buy rating on the shares after its Q4 results. The company’s outlook is also suggesting a healthy Brukinsa growth, even without any major label expansion, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- BeOne Medicines price target raised to $425 from $417 at RBC Capital
- BeOne Medicines price target raised to $410 from $400 at Guggenheim
- BeOne Medicines price target raised to $405 from $394 at Barclays
- BeOne Medicines reports Q4 adjusted EPS $1.95, consensus $1.30
- BeOne Medicines sees 2026 revenue $6.2B-$6.4B, consensus $6.44B